Switching to second line MS disease-modifying therapies is associated with decreased relapse rate

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate

Background and objectivesWhile randomized, controlled trials (RCTs) are the gold standard for determining treatment efficacy, they do not capture the effectiveness of treatment during real-world use. We aimed to evaluate the association between demographics and multiple sclerosis (MS) disease-modify...

Full description

Bibliographic Details
Main Authors: James John Marriott, Okechukwu Ekuma, Randall Fransoo, Ruth Ann Marrie
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
disease-modifying therapy
treatment efficacy
MS relapse
MS epidemiology
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1243589/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1243589/full

Similar Items